Terns Pharmaceuticals to Join UBS Obesity Therapeutics Day

May 17, 2024 – Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical enterprise, announced that its senior management will engage in a virtual fireside chat at UBS Obesity Therapeutics Day. The event is scheduled for Thursday, May 23, 2024, at 1:00 p.m. ET.

The discussion will be streamed live on the investor relations section of the Terns Pharmaceuticals website. For those unable to watch the live webcast, a replay will be available on the website for 30 days after the event.

Terns Pharmaceuticals is a clinical-stage firm focused on developing small molecule product candidates targeting serious diseases, with a particular emphasis on oncology and obesity. The company’s development pipeline features three programs in clinical stages. These include an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, and a THR-β agonist. Additionally, Terns is working on a preclinical discovery project to identify a GIPR antagonist as a nominee for further development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!